July 20, 2020 -- Beacon Targeted Therapies has released a new clinical trial and drug database called Beacon Oncolytic Viruses.
The database will offer drug developers the ability to track and monitor markets, competition, and technological and scientific efforts, the company said. The database covers the following metrics:
- Virus type and family
- Genome types
- Genes deleted and transgenes
- Pathway or signaling alternation
- Envelope modifications or promoter-related modifications
- Routes of administration
- Diseases
- Biomarkers
- Line of therapy
The data consists of information taken from a range of sources, including clinical trial registries, scientific journals, company reports, press releases, conference reports and abstracts, and government or regulatory organizations, Beacon said.
Copyright © 2020 scienceboard.net